The story
Patheon was founded in Fort Erie, Ontario in 1974 as Custom Pharmaceuticals Ltd. In 1990, it began to expand to US markets. Custom Pharmaceuticals changed its name to Patheon in 1993 and was first publicly traded that year on the Toronto Stock Exchange.
In 2004, Patheon acquired MOVA, a drug manufacturer based in Puerto Rico, US. The deal proved unprofitable, and in 2007, the New York equity firm JLL Partners provided Patheon $150 million to restructure. Two years later, after a failed takeover bid by Lonza Group, JLL Partners bought a controlling interest in the company.
In December 2012, Patheon acquired Banner Pharmacaps, a drug manufacturer specializing in softgels, for $255 million. (Patheon changed the company's name the following year to "Banner Life Sciences"). In a $2.6 billion deal, Patheon merged with the pharmaceutical division of Royal DSM NV in 2014 to become a joint venture after JLL Partners bought a controlling stake in the latter as well, adding significantly to Patheon's European production capacity.
In 2015, Patheon acquired Agere Pharmaceuticals, an Oregon company specializing in drug solubility, and IRIX, a maker of specialist Active Pharmaceutical Ingredients in South Carolina, the latter for $162.78 million.
On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon for $7.2 billion.
From Wikipedia’s article on Patheon, shared under CC BY-SA 4.0.6